De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sirnaomics Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Alan Patrick Lu

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	47.4%
Dienstverband CEO	4yrs
Eigendom CEO	10.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Alan Patrick Lu's beloning veranderd ten opzichte van Sirnaomics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$82m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$1m	US$515k	-US$79m
Sep 30 2023	n/a	n/a	-US$82m
Jun 30 2023	n/a	n/a	-US$84m
Mar 31 2023	n/a	n/a	-US$86m
Dec 31 2022	US$602k	US$520k	-US$88m
Sep 30 2022	n/a	n/a	-US$230m
Jun 30 2022	n/a	n/a	-US$223m
Mar 31 2022	n/a	n/a	-US$218m
Dec 31 2021	US$4m	US$379k	-US$213m
Sep 30 2021	n/a	n/a	-US$60m
Dec 31 2020	US$370k	US$276k	-US$44m
Dec 31 2019	US$379k	US$277k	-US$16m

Compensatie versus markt: De totale vergoeding ($USD 1.09M ) Alan Patrick } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 234.08K ).

Compensatie versus inkomsten: De vergoeding van Alan Patrick is gestegen terwijl het bedrijf verliesgevend is.

CEO

Alan Patrick Lu (68 yo)

4yrs

Tenure

US$1,086,000

Compensatie

Dr. Yang Lu, also known as Alan Patrick, PhD., is the founder, serves as Chairman of the Board, President & Chief Executive Officer at Sirnaomics Ltd. and has been its Director since October 15, 2020. He w...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yang Lu	CEO, President & Chairman	4yrs	US$1.09m	10.7% $ 34.5m
Xiaochang Dai	Senior Advisor - Drug Development & Commercialization and Executive Director	3.8yrs	US$885.00k	2.03% $ 6.5m
Monin Ung	Independent Non Executive Director	2.8yrs	US$69.00k	geen gegevens
Cheung-Hoi Yu	Independent Non Executive Director	2.8yrs	US$46.00k	geen gegevens
Mo Han Shing	Independent Non-Executive Director	2.8yrs	US$69.00k	geen gegevens
Jiankang Zhang	Non Executive Director	3.3yrs	US$15.00k	geen gegevens
Mincong Huang	Non Executive Director	3.8yrs	US$15.00k	1.1% $ 3.5m

3.3yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2257 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Sirnaomics Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Gore Range Capital LLC and Sirnaomics Ltd. Announces Management of the New Venture Sagesse Bio, Inc

Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director

Sirnaomics Ltd., Annual General Meeting, Jun 20, 2024

Board Member recently sold HK$14m worth of stock

Board Member recently sold HK$8.1m worth of stock

Recent updates

Sirnaomics Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Gore Range Capital LLC and Sirnaomics Ltd. Announces Management of the New Venture Sagesse Bio, Inc

Sirnaomics Ltd. Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases

Sirnaomics Announces Completion Of STP707 Phase I Clinical Study Withstrong Safety Profile and Stable Disease Activityfor the Treatment of Pancreatic Cancer Patients

Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer

Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director

Sirnaomics Ltd., Annual General Meeting, Jun 20, 2024

Board Member recently sold HK$14m worth of stock

New minor risk - Financial data availability

Sirnaomics Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Board Member recently sold HK$8.1m worth of stock

Now 29% undervalued after recent price drop

New major risk - Revenue and earnings growth

Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment

China Chief Scientific Officer recently bought HK$2.8m worth of stock

Sirnaomics Ltd. Announces Executive Changes

Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction

Sirnaomics Ltd. Announces Appointment of Chief Strategy Officer and Resignation of Joint Company Secretary

Sirnaomics Ltd. Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

Sirnaomics Ltd. to Report Q2, 2023 Results on Aug 30, 2023

Sirnaomics Ltd. Appoints Francois Lebel as Senior Vice President for Preclinical and Clinical Development

Sirnaomics Ltd. Establishes Strategic Partnership with Edirna Inc

Sirnaomics Advances STP705 for Squamous Cellcarcinoma in Situ into Late-Stage Clinical development

Sirnaomics Ltd. Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty

Sirnaomics Ltd. Doses the First Participant in Phase I Clinical Study of Galnac-Based Rnai Therapeutic STP122G for Anticoagulant Treatment

Sirnaomics Ltd. to Receive Subsidy for Subsidy HKSTP Clinical Translational Catalyst Plan

China Chief Scientific Officer recently sold HK$3.0m worth of stock

Board Member exercised options and sold HK$2.2m worth of stock

Sirnaomics Ltd. Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers

China Chief Scientific Officer exercised options to buy HK$22m worth of stock.

China Chief Scientific Officer recently sold HK$702k worth of stock

Sirnaomics Ltd. Announces Interim Data from Phase I Clinical Trial of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors

Sirnaomics Ltd. Announces Positive Interim Datafrom Phase IIB Clinical Trial of Stp705 in Adultswith Cutaneous Squamous Cell Carcinoma in Situ

Sirnaomics Ltd. Announces CFO Changes

Less than half of directors are independent

Sirnaomics Ltd. Announces Estimated Commercialization Timeline of STP705

Sirnaomics Ltd. Doses First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment

China Chief Scientific Officer recently sold HK$1.7m worth of stock

Sirnaomics to Present Latest Developments on Sirna Therapeutics for Cancer and Galaheadtm Platform Programs At the 2Nd Annual Oligonucleotide Therapeutics and Delivery Conference

China Chief Scientific Officer exercised options to buy HK$14m worth of stock.

Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Ltd. Advances Galahead-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

Sirnaomics Ltd. Announces Resignation of Mr. Da Liu as Non-Executive Director with Effect from September 30, 2022

Sirnaomics Ltd. Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer in SITU

Sirnaomics Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

Sirnaomics Ltd. Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

Sirnaomics Ltd. Announces Board Changes

Sirnaomics Ltd. Announces Publication of STP705 Clinical Study Results for Treatment of is SCC in the Peer-Reviewed Journal of Drugs in Dermatology

Sirnaomics Ltd. Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment

Non Executive Director recently sold HK$2.1m worth of stock

Sirnaomics Ltd. Presents Clinical Study Results and Development Strategy for Cancer RNA Therapeutics At the 2022 Pre-Asco China Summit

Less than half of directors are independent

Sirnaomics Ltd. Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis

Sirnaomics Ltd., Annual General Meeting, Jun 28, 2022

Sirnaomics Ltd. to Report Fiscal Year 2021 Results on Mar 31, 2022

Sirnaomics Ltd. Announces Interim Data from Phase II Clinical Trial of Stp705 for Treatment of Cutaneous Basal Cell Carcinoma

Sirnaomics Ltd. Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

Sirnaomics Launches Phase I Clinical Trial of Rnai Therapeutic Stp707 Delivered Systemically for the Treatment of Solid Tumors

Non Executive Director recently bought HK$371k worth of stock

Non Executive Director recently bought HK$11m worth of stock

Less than half of directors are independent

Sirnaomics Ltd. has completed an IPO in the amount of HKD 496.886 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur